Evidence map›Paper›PMID 39888516›Full record

ArticleInternational journal of hematology2025

Chronic graft-versus-host disease myelitis successfully treated with rituximab.

Emi Yokoyama, Yuta Hasegawa, Kentaro Wakaki, Touma Suzuki, Sayaka Kajikawa, Minoru Kanaya, Koh Izumiyama, Makoto Saito, Masanobu Morioka, Jun Nagai and 10 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Emi YokoyamaBlood Disorders Center, Aiiku Hospital, S4W25, Chuo-ku, Sapporo, 064-0804, Japan. chatte_brillante@yahoo.co.jp.
Yuta HasegawaDepartment of Hematology, Hokakido University Hospital, Sapporo, Japan.
Kentaro WakakiDepartment of Rehabilitation, Aiiku Hospital, Sapporo, Japan.
Touma SuzukiBlood Disorders Center, Aiiku Hospital, S4W25, Chuo-ku, Sapporo, 064-0804, Japan.
Sayaka KajikawaBlood Disorders Center, Aiiku Hospital, S4W25, Chuo-ku, Sapporo, 064-0804, Japan.
Minoru KanayaBlood Disorders Center, Aiiku Hospital, S4W25, Chuo-ku, Sapporo, 064-0804, Japan.
Koh IzumiyamaBlood Disorders Center, Aiiku Hospital, S4W25, Chuo-ku, Sapporo, 064-0804, Japan.
Makoto SaitoBlood Disorders Center, Aiiku Hospital, S4W25, Chuo-ku, Sapporo, 064-0804, Japan.
Masanobu MoriokaBlood Disorders Center, Aiiku Hospital, S4W25, Chuo-ku, Sapporo, 064-0804, Japan.
Jun NagaiDepartment of Hematology, Hokakido University Hospital, Sapporo, Japan.
Tomoe IchikiDepartment of Hematology, Hokakido University Hospital, Sapporo, Japan.
Ryo KikuchiDepartment of Hematology, Hokakido University Hospital, Sapporo, Japan.
Satomi OkadaDepartment of Hematology, Hokakido University Hospital, Sapporo, Japan.
Hiroyuki OhigashiDepartment of Hematology, Hokakido University Hospital, Sapporo, Japan.
Hideki GotoDepartment of Hematology, Hokakido University Hospital, Sapporo, Japan.
Masahiro OnozawaDepartment of Hematology, Hokakido University Hospital, Sapporo, Japan.
Daigo HashimotoDepartment of Hematology, Hokakido University Hospital, Sapporo, Japan.
Akio MoriBlood Disorders Center, Aiiku Hospital, S4W25, Chuo-ku, Sapporo, 064-0804, Japan.
Takanori TeshimaDepartment of Hematology, Hokakido University Hospital, Sapporo, Japan.
Takeshi KondoBlood Disorders Center, Aiiku Hospital, S4W25, Chuo-ku, Sapporo, 064-0804, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic graft-versus-host disease (cGVHD) is a major serious complication after allogeneic stem-cell transplantation (allo-HSCT), and often mimics autoimmune diseases. Central nervous system (CNS) symptoms are rare manifestations of cGVHD, and are difficult to diagnose. CNS manifestations of cGVHD were discussed in the 2020 National Institutes of Health cGVHD Consensus Project as one of the "atypical cGVHD manifestations" with involvement of various organ systems other than classical cGVHD organs. We experienced a case of myelitis after allo-HSCT diagnosed as cGVHD of the CNS. The neurological symptoms progressed after corticosteroid pulse therapy, resulting in severe paralysis and paresthesia of the lower extremities. The clinical course and magnetic resonance imaging findings showed some similarities with multiple sclerosis. We decided to use rituximab after the patient became refractory to corticosteroids because rituximab has been reported to be effective in multiple sclerosis by suppressing B cells on both sides of the blood-brain barrier. Rituximab was effective for the neurologic symptoms in our case. In atypical cGVHD, treatments used in corresponding autoimmune diseases may be reasonable and effective.

Indexed as

Graft vs Host DiseaseHematopoietic Stem Cell TransplantationMyelitisRituximabChronic DiseaseHumansMagnetic Resonance ImagingTreatment OutcomeRituximabAllogeneic stem-cell transplantationAtypical chronic graft-versus-host diseaseCentral nervous systemMyelitisRituximab

Identifiers

PMID39888516
PMCPMC12014695

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.